Abstract 526P
Background
Tracheal, Bronchus, and Lung (TBL) cancer is the 1st leading cause of deaths across Southeast Asia (SEA), East Asia (EA), and Oceania (OC). However, there has been a lack of estimates regarding the burden of TBL cancer across these regions in previous studies.
Methods
Utilizing the Global Burden of Disease Methodology, TBL cancer prevalence, incidence, mortality, and disabiity adjusted life years (DALYs) were analyzed by age, sex, year, across SEA, EA, and OC spanning from 1990-2019. We employed a regression framework to forecast TBL cancer deaths through 2040.
Results
The total prevalence of TBL cancer cases surged by 3.5 times, escalating from 344,251 (95% uncertainty interval: 301,687-388,590) in 1990 to 1,306,745 (1,116,313-1,513,254) in 2019. While deaths rose from 319,128 (282,904-359,206) to 914,442 (791,095-1,049,894) from 1990-2019. In terms of the age-standardized incidence rate (ASIR), there was an increase from 27.81 (24.65-31.15) to 37.13 (32.08-42.53) per 100,000 person years from 1990-2019. The highest annual percentage of change (APC) was witnessed in deaths, rising by 187%, and in DALYs, increasing by 143% from 1990-2019. Notably, China experienced the highest APC in ASIR (38%), followed by Indonesia (35%), and Taiwan (28%) from 1990-2019. Meanwhile, Indonesia exhibited the highest increase in age-standardized mortality rate (ASMR) at 36%, while the Maldives demonstrated the most notable decrease of 33% from 1990-2019. In 2019, individuals aged 65-69 accounted for the highest incidence (172,031), while those aged 70-74 saw the highest mortality (155,538). Moreover, male individuals consistently bore a greater burden than females over the past three decades. Projection indicates that the total number of deaths may reach 1,080,050 (705,751-1,800,670) by 2040.
Conclusions
TBL cancer constituted 26.21% of all deaths within the realm of cancer-related fatalities in SEA, EA, and OC in 2019. This study uncovers a consistent pattern of escalating burden, emphasizing a notable rise in fatalities and its implications for public health, necessitates comprehensive strategies that encompass both individual risk factors and systemic challenges.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
320P - Treatment patterns and outcomes in Indian patients with advanced ovarian cancer: A single center experience
Presenter: Pushpendra Hirapara
Session: Poster Display
Resources:
Abstract
321P - Epidemiology and survival analysis of epithelial ovarian cancer: Results from comprehensive care center in north India
Presenter: Amit Badola
Session: Poster Display
Resources:
Abstract
322P - Evaluation of chemotherapy response score as a prognostic factor in advanced epithelial ovarian cancer: A prospective single centre study
Presenter: Upasana Palo
Session: Poster Display
Resources:
Abstract
323P - Platelet-to-lymphocyte ratio, neutrophil-to-lymphocyte ratio, and lymphocyte-to-monocyte ratio as prognostic biomarkers in ovarian cancer among the Asian population: A meta-analysis
Presenter: Wikania Wira Wiguna I Gede
Session: Poster Display
Resources:
Abstract
324P - All-<italic>trans</italic> retinoic acid sensitizes ovarian cancer to niraparib by inhibiting ALDH1A1 activity
Presenter: Bingjie Mei
Session: Poster Display
Resources:
Abstract
325TiP - A phase III randomized controlled trial in primary stage three and four ovarian cancer after interval cytoreductive surgery (FOCUS/KOV-HIPEC-04)
Presenter: Myong Cheol Lim
Session: Poster Display
Resources:
Abstract
327TiP - A single arm phase II study of single agent pemetrexed in platinum resistant/refractory epithelial ovarian or primary peritoneal cancer
Presenter: Swasthik Parampalli
Session: Poster Display
Resources:
Abstract
337P - Demographic patterns and survival outcomes of patients with T and NK-cell lymphoma at the National Cancer Centre Singapore
Presenter: Mohamed Haniffa Bin Hasan Mohamed
Session: Poster Display
Resources:
Abstract
338P - Multicenter real-world study of advanced-stage non-nasal type NK/T cell lymphoma (NKTCL): Clinical features, treatment and prognosis
Presenter: Yuce Wei
Session: Poster Display
Resources:
Abstract
339P - A comparison of survival of patients with relapsed or refractory diffuse large B cell lymphoma undergoing allogeneic stem cell transplantation or receiving CAR-T therapy
Presenter: Kenta Hayashino
Session: Poster Display
Resources:
Abstract